文献速递炎症性肠病

老年起病炎症性肠病的流行病学:一项全国性人群队列研究

Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-30

该研究基于丹麦全国患者登记数据,纳入1980至2018年间≥60岁新诊断的克罗恩病和溃疡性结肠炎患者,比较≥70岁起病(极晚发)与60-69岁起病(晚发)患者的发病率趋势、住院、治疗模式及并发症风险,发现极晚发起病者疾病修饰治疗和手术负担更低,但严重感染和心血管事件风险更高。

要点

  • 极晚发与晚发起病的炎症性肠病发病率变化趋势一致。
  • 极晚发患者免疫调节剂或肿瘤坏死因子拮抗剂使用及主要手术显著低于晚发患者。
  • 极晚发患者5年严重感染和心血管事件风险高于晚发患者。

核心结论

  • 该全国性队列研究显示,与晚发炎症性肠病相比,极晚发(≥70岁)患者疾病和衰老相关并发症的相对负担更高,而使用 sparing 类固醇策略和手术有限。

研究设计与样本

  • 基于丹麦全国患者登记数据库的全国性人群队列研究,纳入1980至2018年间≥60岁新诊断的克罗恩病和溃疡性结肠炎患者。

主要发现

  • 共识别≥60岁起病克罗恩病患者3459例(47%≥70岁)和溃疡性结肠炎患者10774例(51%≥70岁)。
  • 极晚发与晚发患者炎症性肠病相关住院和皮质类固醇使用的累积发生率相当。
  • 极晚发患者免疫调节剂或肿瘤坏死因子拮抗剂使用及主要炎症性肠病相关手术负担显著低于晚发患者。
  • 极晚发患者5年严重感染和心血管事件风险高于晚发患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We examined the incidence and natural history of patients with very elderly onset (herein referred to as very late-onset) inflammatory bowel diseases (IBDs) (≥ 70 years of age at diagnosis), compared with patients diagnosed between 60 and 69 years of age in Denmark. METHODS: In the Danish National Patient Register, between 1980 and 2018, we identified all individuals ≥ 60 years of age with newly diagnosed Crohn's disease (CD) and ulcerative colitis (UC) and examined trends in incidence, cumulative risk of hospitalization, treatment patterns, IBD-related surgery, serious infection, cancer and cardiovascular and venous thromboembolic risks among very late-onset (70-79 years of age or 80+ years) vs late-onset (60-69 years of age) IBD, using nonparametric competing risk analysis treating death as competing risk. RESULTS: We identified 3459 patients with onset of CD at ≥60 years of age (47% ≥ 70 years of age) and 10,774 patients with onset of UC ≥60 years of age (51% ≥ 70 years of age). Over the last 3 decades, incidence changes for very late-onset and late-onset IBD have followed the same patterns. Also, both for CD and UC, cumulative incidence of IBD-related hospitalization and corticosteroid use was comparable in very late-onset vs late-onset patients. However, the burden of disease-modifying therapy, either immunomodulator or tumor necrosis factor antagonist use, and major IBD-related surgery was significantly lower in patients with very late-onset than in late-onset IBD. On the other hand, the 5-year risk of serious infections and cardiovascular events was higher in patients with very late-onset IBD. CONCLUSIONS: This nationwide cohort study shows that patients diagnosed with very late-onset (≥ 70 years of age) IBD have a higher relative burden of disease- and aging-related complications, with limited use of steroid-sparing strategies and surgery, compared with late-onset IBD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singh S, Poulsen GJ, Bisgaard TH, et al. Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study. Clin Gastroenterol Hepatol. 2024. PMID: 39209204. doi:10.1016/j.cgh.2024.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。